Review
Thrombotic microangiopathies: a general approach to diagnosis and management
Donald M. Arnold, Christopher J. Patriquin and Ishac Nazy
CMAJ January 30, 2017 189 (4) E153-E159; DOI: https://doi.org/10.1503/cmaj.160142
Donald M. Arnold
Michael G. DeGroote School of Medicine, Department of Medicine (Arnold, Patriquin, Nazy), McMaster University; Canadian Blood Services (Arnold), Hamilton, Ont.
MD, MScChristopher J. Patriquin
Michael G. DeGroote School of Medicine, Department of Medicine (Arnold, Patriquin, Nazy), McMaster University; Canadian Blood Services (Arnold), Hamilton, Ont.
MD, MScIshac Nazy
Michael G. DeGroote School of Medicine, Department of Medicine (Arnold, Patriquin, Nazy), McMaster University; Canadian Blood Services (Arnold), Hamilton, Ont.
PhD
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
Thrombotic microangiopathies: a general approach to diagnosis and management
Donald M. Arnold, Christopher J. Patriquin, Ishac Nazy
CMAJ Jan 2017, 189 (4) E153-E159; DOI: 10.1503/cmaj.160142
Jump to section
- Article
- What are thrombotic microangiopathies?
- How are thrombotic microangiopathies classified?
- How is the diagnosis of thrombotic microangiopathy made?
- What is the initial treatment for thrombotic microangiopathies?
- What is the treatment for relapsed or refractory thrombotic microangiopathy?
- What is the role of ADAMTS13 testing?
- Unanswered questions
- Conclusion
- Acknowledgements
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- Clopidogrel-induced thrombotic microangiopathy: a case report
- Dedifferentiated liposarcoma with heterologous rhabdomyosarcomatous differentiation in the bone marrow
- Persistent renal replacement requirement following fulminant psittacosis infection in pregnancy
- A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment
- Platelet Activating Immune Complexes Identified in COVID-19 Associated Coagulopathy
- Adalimumab as a potential cause of drug-induced thrombocytopaenic microangiopathy
- Thrombotic thrombocytopenic purpura masquerading as a stroke in a young man